Dulera
NDC Package 0085-7206-07
Package Information
Dulera is a medication used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. Marketed by Merck Sharp & Dohme Corp., this product is identified by NDC 0085-7206 and is authorized under FDA application NDA022518.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0085 - Merck Sharp & Dohme Corp.
- 0085-7206 - Dulera
- 0085-7206-07 - 1 CANISTER in 1 CARTON / 60 AEROSOL in 1 CANISTER
- 0085-7206 - Dulera
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0085-7206). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0085-7206-07 identifies a specific commercial package of 1 canister in 1 carton / 60 aerosol in 1 canister of Dulera, labeled by Merck Sharp & Dohme Corp.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Merck Sharp & Dohme Corp. on June 22, 2010. The current certification is valid through December 31, 2021.
What are the primary indications for this medication?
This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: mometasone and formoterol. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. This product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.
How is this Merck Sharp & Dohme Corp. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00085720607. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.